International AIDS society conference 2023 summary
© 2023 British HIV Association..
AIM: This article summarizes key research presented at the International AIDS Society (IAS) Conference in Brisbane, held in July 2023.
CO-MORBIDITIES: The REPRIEVE Trial as a conference highlight, demonstrating significantly fewer major cardiovascular events amongst people with HIV who were randomized to pitavastatin compared to placebo. Key data on weight, hypertension and incident diabetes are also summarized.
ANTIRETROVIRAL THERAPY: Novel data on doravirine and islatravir are described as are trials demonstrating efficacy dolutegravir/lamivudine first-line in people without baseline resistance testing and in suppressed switch amongst people with historic lamivudine resistance.
HIV CURE: The sixth case of HIV cure secondary to stem cell transplantation is summarized, as are new insights into the central nervous system as an HIV reservoir.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
HIV medicine - 25(2024), 2 vom: 01. Feb., Seite 168-173 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Waters, Laura [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2T8Q726O95 |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/hiv.13563 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363651659 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363651659 | ||
| 003 | DE-627 | ||
| 005 | 20240215231924.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/hiv.13563 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1294.xml |
| 035 | |a (DE-627)NLM363651659 | ||
| 035 | |a (NLM)37872882 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Waters, Laura |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a International AIDS society conference 2023 summary |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 British HIV Association. | ||
| 520 | |a AIM: This article summarizes key research presented at the International AIDS Society (IAS) Conference in Brisbane, held in July 2023 | ||
| 520 | |a CO-MORBIDITIES: The REPRIEVE Trial as a conference highlight, demonstrating significantly fewer major cardiovascular events amongst people with HIV who were randomized to pitavastatin compared to placebo. Key data on weight, hypertension and incident diabetes are also summarized | ||
| 520 | |a ANTIRETROVIRAL THERAPY: Novel data on doravirine and islatravir are described as are trials demonstrating efficacy dolutegravir/lamivudine first-line in people without baseline resistance testing and in suppressed switch amongst people with historic lamivudine resistance | ||
| 520 | |a HIV CURE: The sixth case of HIV cure secondary to stem cell transplantation is summarized, as are new insights into the central nervous system as an HIV reservoir | ||
| 650 | 4 | |a Congress | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a IAS | |
| 650 | 4 | |a antiretroviral | |
| 650 | 4 | |a co-morbidities | |
| 650 | 4 | |a conference | |
| 650 | 4 | |a cure | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Lamivudine |2 NLM | |
| 650 | 7 | |a 2T8Q726O95 |2 NLM | |
| 700 | 1 | |a Hassan Wada, Yusuf |e verfasserin |4 aut | |
| 700 | 1 | |a Barber, Tristan J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t HIV medicine |d 1999 |g 25(2024), 2 vom: 01. Feb., Seite 168-173 |w (DE-627)NLM116282541 |x 1468-1293 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2024 |g number:2 |g day:01 |g month:02 |g pages:168-173 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/hiv.13563 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2024 |e 2 |b 01 |c 02 |h 168-173 | ||